This Article Full Text (PDF) All Versions of this Article: 1756285609344375v1 2/6/357    most recent References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Scopus Google Scholar Articles by Awad, A. Articles by Stüve, O. Social Bookmarking                         What's this?

Review: Cyclophosphamide in multiple sclerosis: scientific rationale, history and novel treatment paradigms

Department of Neurology, University of Texas Southwestern Medical Center at Dallas, TX, USA

Olaf Stüve

Departments of Neurology and Immunology, University of Texas Southwestern Medical Center at Dallas, TX, USA, Neurology Section, VA North Texas Health Care System, Medical Service, Dallas, TX, USA, olaf.stuve@ utsouthwestern.edu

For patients with relapsing-remitting multiple sclerosis (RRMS), there are currently six approved medications that have been shown to alter the natural course of the disease. The approved medications include three beta interferon formulations, glatiramer acetate, natalizumab and mitoxantrone. Treating aggressive forms of RRMS and progressive disease forms of MS still presents a great challenge to neurologists. Intense immunosuppression has long been thought to be the only feasible therapeutic option. In patients with progressive forms of MS, lymphoid tissues have been detected in the central nervous system (CNS) that may play a critical role in perpetuating local inflammation. Agents that are currently approved for patients with MS have no or very limited bioavailability in the brain and spinal cord. In contrast, cyclophosphamide (CYC), an alkylating agent, penetrates the blood-brain barrier and CNS parenchyma well. However, while CYC has been used in clinical trials and off-label in clinical practice in patients with MS for over three decades, data on its efficacy in very heterogeneous groups of study patients have been conflicting. New myeloablative treatment paradigms with CYC may provide a therapeutic option in patients that do not respond to other agents. In this article we review the scientific rationale that led to the initial clinical trials with CYC. We will also outline the safety, tolerability and efficacy of CYC and provide neurologists with guidelines for its use in patients with MS and other inflammatory disorders of the CNS, including neuromyelitis optica (NMO). Finally, an outlook into relatively novel treatment approaches is provided.

Key Words: multiple sclerosis • MS • Cytoxan • cyclophosphamide • treatment • therapy • immunology

This version was published on November 1, 2009

Therapeutic Advances in Neurological Disorders, Vol. 2, No. 6, 357-368 (2009)
DOI: 10.1177/1756285609344375


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?